NYXH

Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026 Mont-Saint-Guibert, Belgium – October 26, 2026, 10:05 pm CET / 5:05 pm ET – Nyxoah SA (Euronext Brussels/NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the third quarter of 2026 on Thursday, November 5, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30 pm CET / 4:30 pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah w

6-K - Nyxoah SA (0001857190) (Filer)

REGULATED INFORMATIONINSIDE INFORMATION Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026 U.S. net revenue grows 29% sequentially, driving third quarter global preliminary net revenue of €9.2 millionPMA supplement submitted to the FDA to expand Genio’s U.S. indication to Complete Concentric Collapse patients Mont-Saint-Guibert, Belgium – October 19, 2026, 2:00 pm CET / 08:00 am ET – Nyxoah SA (Euronext Brussels/NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported certain preliminary unaudited th

Full 12-Month Data from the ACCCESS U.S. Pivotal Study in Complete Concentric Collapse Patients Presented at ISSS 2026 Genio® bilateral stimulation delivered a 74.3% median reduction in AHI at 12 months, with no device- or procedure-related serious adverse events PMA supplement submitted to the FDA to expand Genio’s indication to CCC patients Mont-Saint-Guibert, Belgium – October 15, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the complete 12-month results of the ACCCESS U

6-K - Nyxoah SA (0001857190) (Filer)

REGULATED INFORMATIONINSIDE INFORMATION Nyxoah Appoints Liam Kelly as Chief Executive Officer Further strengthening the Company’s strategic U.S. presence and focus Mont-Saint-Guibert, Belgium – September 28, 2026, 10:30 pm CET / 4:30 pm ET – Nyxoah SA (Euronext Brussels/NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of Liam Kelly as Chief Executive Officer, effective October 1, 2026, succeeding Olivier Taelman. The appointment reflects Nyxoah’s continued evolution into a U.S.-focused commercial organization following FDA appr

6-K - Nyxoah SA (0001857190) (Filer)

MINNEAPOLIS, Sept. 21, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that John Landry has been appointed Chief Financial Officer, succeeding Jared Oasheim, whose resignation was previously announced. Mr. Landry will join the Company on October 12, 2026, and assume the CFO role on the day after the Company files its Form 10-Q for the quarter ending September 30, 2026.   Mr. Oasheim will remain with the Company for a transition period consistent with his previously disclosed transition

REGULATED INFORMATIONINSIDE INFORMATION Nyxoah Announces Chief Financial Officer Transition Loïc Moreau, Nyxoah’s President International and former CFO, to serve as interim CFO Company reaffirms full year 2026 financial guidance Mont-Saint-Guibert, Belgium – September 21, 2026, 22:01h CET / 4:01h ET – Nyxoah SA (Euronext Brussels/NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that John Landry, Chief Financial Officer, will step down from his role effective October 2, 2026 to pursue another professional opportunity. Loïc Moreau, the Company’

Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System BREATHE is scheduled to implant up to 229 patients at up to 25 U.S. centers, followed for up to five years, to evaluate the long-term safety and effectiveness of the Genio therapy in real-world clinical practice First implant performed by Rolando Molina, MD, South Florida ENT Associates, with Edward Mezerhane, MD, of PharmaDev Clinical Research Institute as Site Principal Investigator Mont-Saint-Guibert, Belgium – September 7, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough tr

REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients Reports an Apnea-Hypopnea Index (AHI) responder rate of 77.2% on a Full Analysis Set basis (p<0.001) Zero device-related serious adverse events through 12 months Mont-Saint-Guibert, Belgium – September 2, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the ACCCESS U.S. pivotal study achieved statistically sig

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), August 25, 2026, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issuance of 1,767,402 new shares on August 20, 2026 in connection with the contribution in kind of a receivable held by the holder of the convertible bonds issued by the Company on December 18, 2025. For more information on this transaction, please refer to the special report of the board of directors dated August 19, 20261. Share capital: EUR 7,0

SCHEDULE 13G/A - Nyxoah SA (0001857190) (Subject)

6-K - Nyxoah SA (0001857190) (Filer)

REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results U.S. commercial execution driving continued launch momentum resulting in 22% sequential U.S. revenue growth in Q2 2026 over Q1 2026 Mont-Saint-Guibert, Belgium – August 5, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the second quarter and first half of 2026. Financial and Operating Highlights Financials U.S. net revenue for the second q

Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026 Mont-Saint-Guibert, Belgium – July 27, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the second quarter of 2026 on Wednesday, August 5, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah'

6-K - Nyxoah SA (0001857190) (Filer)

Nyxoah Announces Preliminary Results for the Second Quarter of 2026 Continued U.S. launch momentum drives second quarter global preliminary net revenue of €7.7 millionCMS proposes 2027 OPPS and ASC payment increase of 12% and 15% respectively Mont-Saint-Guibert, Belgium – July 7, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported certain preliminary unaudited second quarter 2026 financial and operating results. Second Quarter 2026 – Preliminary Sales and Market Metrics Financials Gl

SCHEDULE 13G/A - Nyxoah SA (0001857190) (Subject)

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 30, 2026, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of May 2, 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issuance of 146,531 new shares on June 30, 2026 following the exercise of so-called "restricted share units". Share capital: EUR 7,075,152.31 Total number of securities carrying voting rights: 100,072,815 (all ordinary shares) Total number of voting rights (= denominator): 100,072,815 (all relating to ordinary shares)Number of rights to subscribe t

         REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), June 29, 2026, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Law of May 2, 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received transparency notifications as detailed below. Orin Hirchman On June 24, 2026, Nyxoah received a transparency notification from Orin Hirchman following an acquisition of voting securities by entities controlled by Orin Hirchman. Based on the notification, on June 10, 2026, the entities controlled by Orin Hirchman held 14,534,880 voting rights, representing 14.55% of the

6-K - Nyxoah SA (0001857190) (Filer)

Nyxoah to Host Investor Day in New York on July 8, 2026 Leadership team and Board will discuss the U.S. commercial execution, growth strategy and key priorities Mont-Saint-Guibert, Belgium – June 23, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA), today announced that it will host an Investor and Analyst Day on Wednesday, July 8, 2026, in New York. The event will be held at the offices of Bank of America and will run from 10:00 AM to 12:30 PM ET (16:00 to 18:30 CET). The event will be webcast live for those unable to attend in

SCHEDULE 13G - Nyxoah SA (0001857190) (Subject)

REGULATED INFORMATIONJune 19, 2026, 10:30pm CET / 4:30pm ET NYXOAH SA(Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the "Company") Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 9, 2026 The board of directors of the Company is pleased to invite its securities holders to attend the extraordinary shareholders' meeting of the Company, to be held on Thursday, July 9, 2026 at 2:00 p.m. CET at the Company's seat, or at such other place as will be indicated prior to such time. The Company will also set up a video conference to allow holders of securities of the Company who have duly registered